亚宝药业(600351) - 2021 Q3 - 季度财报

Major Financial Data Key Accounting Data and Financial Indicators The company achieved 2.206 billion Yuan in operating revenue and 145 million Yuan in net profit attributable to shareholders in the first three quarters of 2021, growing by 19.13% and 58.09% respectively, with strong third-quarter performance Key Financial Indicators for the First Three Quarters of 2021 | Indicator | Year-to-Date (Yuan) | Year-on-Year Growth (%) | | :--- | :--- | :--- | | Operating Revenue | 2,205,654,088.29 | 19.13% | | Net Profit Attributable to Shareholders | 145,274,815.46 | 58.09% | | Net Profit Attributable to Shareholders (Excl. Non-recurring) | 124,305,817.40 | 80.65% | | Net Cash Flow from Operating Activities | 274,607,162.87 | 16.58% | | Basic Earnings Per Share | 0.1887 Yuan/share | 58.17% | Key Financial Indicators for Q3 2021 | Indicator | Current Period (Q3) (Yuan) | Year-on-Year Growth (%) | | :--- | :--- | :--- | | Operating Revenue | 740,749,708.96 | 5.88% | | Net Profit Attributable to Shareholders | 45,949,685.70 | 48.95% | | Net Profit Attributable to Shareholders (Excl. Non-recurring) | 36,600,113.22 | 68.02% | Key Balance Sheet Indicators as of September 30, 2021 | Indicator | Period-End Balance (Yuan) | Growth from End of Previous Year (%) | | :--- | :--- | :--- | | Total Assets | 4,136,535,153.47 | 3.05% | | Total Equity Attributable to Shareholders | 2,885,174,862.79 | 3.84% | Non-recurring Gains and Losses Items and Amounts Total non-recurring gains and losses for the first three quarters of 2021 were 20.969 million Yuan, primarily driven by 22.1922 million Yuan in government grants Key Non-recurring Gains and Losses Items for the First Three Quarters of 2021 | Item | Year-to-Date Amount (Yuan) | | :--- | :--- | | Government Grants Recognized in Current Period P&L | 22,192,224.04 | | Other Non-operating Income and Expenses | -4,636,769.29 | | Reversal of Impairment Provisions for Receivables | 3,975,934.93 | | Capital Occupation Fees Received from Non-financial Enterprises | 2,407,803.87 | | Fair Value Changes in Trading Financial Assets/Liabilities | 1,723,869.87 | | Total | 20,968,998.06 | Analysis of Changes in Key Financial Indicators Significant performance growth in the first three quarters of 2021 is attributed to increased sales of core high-margin products like Dingguier Umbilical Paste and Xiaozhong Zhitong Paste - Operating revenue increased by 19.13% year-on-year, primarily due to increased sales volume of key products such as Dingguier Umbilical Paste and Xiaozhong Zhitong Paste[10] - Net profit attributable to shareholders and net profit attributable to shareholders after deducting non-recurring gains and losses significantly increased by 58.09% and 80.65% respectively, mainly benefiting from increased revenue and a higher proportion of sales from high-margin products like Dingguier Umbilical Paste and Xiaozhong Zhitong Paste[10] Shareholder Information Shareholding Status of Shareholders As of September 30, 2021, the company had 45,373 common shareholders, with Shanxi Yabao Investment Group Co., Ltd. as the largest, holding 12.25% of shares, some pledged - As of the end of the reporting period, the company had a total of 45,373 common shareholders[12] Top Ten Shareholders' Shareholding Status | Shareholder Name | Shareholding Ratio (%) | Number of Shares Held | Share Status | | :--- | :--- | :--- | :--- | | Shanxi Yabao Investment Group Co., Ltd. | 12.25 | 94,300,000 | Pledged 53,200,000 | | Guangdong Jin Ya Relief Equity Investment Partnership | 6.18 | 47,600,000 | None | | Shanxi Provincial Economic Construction Investment Group Co., Ltd. | 3.36 | 25,891,756 | None | | Lingding No. 17 Private Securities Investment Fund | 2.17 | 16,699,920 | None | | Yinwan Quanying No. 13 Private Securities Investment Fund | 1.52 | 11,700,000 | None | Other Important Reminders Other Important Information The company confirms no other important information regarding its operating performance requires special investor attention during the reporting period - The company confirms that there is no other important information regarding its operating performance during the reporting period that requires investor attention[15] Quarterly Financial Statements Type of Audit Opinion The company's financial statements for the third quarter of 2021 are unaudited - The financial statements for this quarter are unaudited[15] Financial Statements As of September 30, 2021, total assets were 4.137 billion Yuan, with first three quarters' operating revenue of 2.206 billion Yuan, net profit of 145 million Yuan, and net operating cash flow of 275 million Yuan Consolidated Balance Sheet As of September 30, 2021, total assets were 4.137 billion Yuan (up 3.05%), and equity attributable to owners of the parent was 2.885 billion Yuan (up 3.84%), with cash increasing to 467 million Yuan Key Balance Sheet Item Changes | Item | September 30, 2021 (Yuan) | December 31, 2020 (Yuan) | Change Rate | | :--- | :--- | :--- | :--- | | Cash and Cash Equivalents | 467,089,145.91 | 350,412,333.61 | 33.29% | | Accounts Receivable | 519,951,763.88 | 468,930,397.71 | 10.88% | | Inventories | 457,382,535.23 | 498,010,506.09 | -8.16% | | Total Assets | 4,136,535,153.47 | 4,014,286,809.26 | 3.05% | | Short-term Borrowings | 610,634,138.88 | 628,318,703.73 | -2.81% | | Total Liabilities | 1,211,630,807.89 | 1,195,932,361.84 | 1.31% | | Equity Attributable to Owners of the Parent | 2,885,174,862.79 | 2,778,411,394.41 | 3.84% | Consolidated Income Statement Total operating revenue for the first three quarters of 2021 grew 19.13% to 2.206 billion Yuan, with R&D expenses up 88.32% to 114 million Yuan, and net profit attributable to owners of the parent increasing 58.09% to 145 million Yuan Key Income Statement Item Changes (Q1-Q3 2021 vs Q1-Q3 2020) | Item | Jan-Sep 2021 (Yuan) | Jan-Sep 2020 (Yuan) | Change Rate | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 2,205,654,088.29 | 1,851,474,001.29 | 19.13% | | Operating Cost | 881,406,982.64 | 734,135,209.03 | 20.06% | | Selling Expenses | 817,881,580.63 | 710,561,527.03 | 15.10% | | Research and Development Expenses | 114,483,700.34 | 60,789,397.35 | 88.32% | | Financial Expenses | 13,859,624.64 | 25,336,838.61 | -45.30% | | Total Profit | 166,254,070.61 | 106,800,390.53 | 55.67% | | Net Profit Attributable to Owners of the Parent | 145,274,815.46 | 91,891,051.07 | 58.09% | Consolidated Cash Flow Statement Net cash flow from operating activities was 275 million Yuan (up 16.58%) in the first three quarters of 2021; net cash outflow from investing activities expanded to 103 million Yuan, while financing cash outflow significantly narrowed Key Cash Flow Statement Items (Q1-Q3 2021 vs Q1-Q3 2020) | Item | Jan-Sep 2021 (Yuan) | Jan-Sep 2020 (Yuan) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 274,607,162.87 | 235,544,718.83 | | Net Cash Flow from Investing Activities | -103,417,346.56 | -70,562,874.59 | | Net Cash Flow from Financing Activities | -67,934,448.73 | -289,389,708.17 | | Net Increase in Cash and Cash Equivalents | 103,224,987.61 | -124,258,327.70 | Adoption and Adjustment of New Lease Standards Effective January 1, 2021, the company adopted new lease standards, adjusting only opening 2021 financial statements to recognize 2.5021 million Yuan in right-of-use assets and 2.4170 million Yuan in lease liabilities - The company adopted the new lease standards on January 1, 2021, using a simplified approach without retrospective adjustment of comparable period information, only adjusting the opening balances for 2021[30] Impact of Adopting New Lease Standards on the January 1, 2021 Balance Sheet | Adjustment Item | Adjusted Amount (Yuan) | | :--- | :--- | | Assets | | | Right-of-Use Assets | +2,502,083.59 | | Prepayments | -85,132.73 | | Liabilities | | | Non-current Liabilities Due Within One Year | +1,138,351.06 | | Lease Liabilities | +1,278,599.80 |